

Author Index

- Aldenderfer PH: See Strelkauskas AJ, 207
Andya J: See Gauny SS, 33
- Bendig MM: See Maeda H, 124
Better M: See Robinson RR, 84
Blottière HM, Steplewski Z, Herlyn D, and Douillard J-Y: Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy, 16
Borrebaeck CAK: See Simonsson AC, 148
Borup-Christensen P: See Ditzel H, 135; Erb K, 215
Brodeur BR: See Larose Y, 67
Brodeur BR, Hamel J, Martin D, and Rondeau P: Biological activity of a human monoclonal antibody to *Bordetella pertussis* lipooligosaccharide, 194
Busch H: See Freeman JW, 4
- Carosella ED: See Hurpin C, 102
Chang CP: See Robinson RR, 84
Chartier J, Jr: See Robinson RR, 84
- DeBoer KF: See McKnight ME, 190
De Silva MG, Ebsworth NM, Dodwell LC, Moyle SP, Swana GT, and Tan KS: Cell lines of novel type derived from a diabetic secrete tissue-reactive human monoclonal antibodies, 11
Ditzel H: See Erb K, 215
Ditzel H, Erb K, Borup-Christensen P, Nielsen B, and Jensenius JC: Evaluation of procedures for the fixation and processing of human tissue for immunohistochemical analysis of human monoclonal antibodies, 135
Dodwell LC: See De Silva MG, 11
Dosako, S: See Shinmoto, H, 39
Douillard, J-Y: See Blottière, HM, 16
- Ebsworth NM: See De Silva MG, 11
Eda Y.: See Maeda H, 124
Elboim HS: See Posner MR, 74
Erb K: See Ditzel H, 135
Erb K, Ditzel H, Waever-Rasmussen J, Borup-Christensen P, Jensenius JC: Antigens recognized by two human monoclonal IgM anticolon cancer antibodies, 16.88 and C-OU1 (B9165), 215
- Foung SKH: See Perkins S, 155
Fox FE: See Kunicka JE, 160
Freeman JW, and Busch H: Monoclonal antibodies to human tumor nucleolar antigens: probes for studying biological function and determining clinical significance, 4
Fry KE: See Larrick JW, 172
- Gauny SS, Andya J, Thomson J, Young JD, and Winkelhake JL: Effect of production method on the systemic clearance rate of a human monoclonal antibody in the rat, 33
Glassy MC: See McKnight ME, 190
Guan XH: See Kresina TF, 42
Gustafsson B, Jondal M, and Sundqvist V-A: SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus, 26
- Hamel J: See Brodeur BR, 194
Hashizume S: See Hirose H, 200; Kato M, 94; Mochizuki K, 116
Hashizume S, Kamei M, Mochizuki K, Sato S, Kuroda K, Kato M, Yasumoto K, Nakahashi H, Hirose H, Tai H, Okano H, Nomoto K, and Murakami H: Serodiagnosis of cancer by using *Candida* cytochrome *c* recognized by human monoclonal antibody HB4C5, 142
Hashizume S, Mochizuki K, Kamei M, Kuroda K, Kato M, Sato S, Yasumoto K, Nakahashi H, Tsuchimoto K, Muraoka M, Nomoto K, and Murakami H: Serodiagnosis of cancer using porcine carboxypeptidase A as an animal antigen recognized by human monoclonal antibody, 51
Herlyn D: See Blottière, HM, 16
Hirose H: See Hashizume S, 142
Hirose H, Sato S, Tai H, Okano H, Yasumoto K, Murakami H, Nomoto K, Matsuyama M, Tamaki S, and Hashizume S: Detection of lung cancer in clinical specimens using a human monoclonal antibody HB4C5-clone 3, 200
Horwitz AH: See Robinson RR, 84
Hurpin C, and Carosella ED: Generation and characterization of secreting and nonsecreting human \times mouse heterohybridomas obtained by in vitro immunization of human peripheral blood lymphocytes, 102
- Jensenius JC: See Ditzel H, 135; Erb K, 215
Jochems, GJ, Klein MR, Jordens R, Pascual-Salcedo D, Van Boxtel-Oosterhof F, van Lier RAW, Zeijlemaker WP: Heterogeneity in both cytokine production and responsiveness of a panel of monoclonal human Epstein-Barr virus-transformed B-cell lines, 57
Jondal M: See Gustafsson B, 26
Jordens R: See Jochems GJ, 57
- Kamei M: See Hashizume S, 51, 142
Kato M: See Hashizume S, 51, 142; Mochizuki K, 116
Kato M, Mochizuki K, Kuroda K, Sato S, Murakami H, Yasumoto K, Nomoto K, and Hashizume S: Histone H2B as an antigen recognized by lung cancer-specific human monoclonal antibody HB4C5, 94
Kimachi K: See Maeda H, 124
Klein MR: See Jochems GJ, 57
Koda K: See McKnight ME, 190
Kresina TF, Guan XH, Posner M, Wisniewski A, and Olds GR: An immunoregulatory human monoclonal antibody in schistosomiasis japonica, 42
Kunicka JE, Fox FE, Seki H, Oleszak EL, and Platsoucas CD: Hybridoma-derived human suppressor factors: Inhibition of growth of tumor cell lines and effect on cytotoxic cells, 160
Kuroda K: See Hashizume S, 51, 142; Kato M, 94
- Larose Y, Tackaberry ES, and Brodeur BR: Human monoclonal antibodies to cytomegalovirus recognize viral epitopes on the surface of virus-infected cells, 67
Larrick JW: See Simonsson AC, 148
Larrick JW, and Fry KE: Recombinant antibodies, 172
- McKnight ME, Prather K, Koda K, DeBoer KF, and Glassy MC: Use of severe combined immunodeficient (SCID) mice to produce human hybridoma ascites, 190
Maeda H, Matsushita S, Eda Y, Kimachi K, Tokiyoshi S, and Bendig MM: Construction of reshaped human antibodies with HIV-neutralizing activity, 124
Martin D: See Brodeur BR, 194
Matsushita S: See Maeda H, 124
Matsuyama M: See Hirose H, 200
Mochizuki K: See Hashizume S, 51, 142; Kato M, 94
Mochizuki K, Kato M, Sato S, Hashizume S, Murakami H, and Nomoto K: Characterization of a lung cancer-associated human monoclonal antibody HB4C5, 116
Moyle SP: See De Silva MG, 11
Murakami H: See Hashizume S, 51, 142; Hirose H, 200; Kato M, 94; Mochizuki K, 116; Shinmoto H, 39
Muraoka M: See Hashizume S, 51
- Nakahashi H: See Hashizume S, 51, 142
Nielsen B: See Ditzel H, 135
Nomoto K: See Hashizume S, 51, 142; Hirose H, 200; Kato M, 94; Mochizuki K, 116
- Okano H: See Hashizume S, 142; Hirose H, 200
Olds GR: See Kresina TF, 42
Oleszak EL: See Kunicka JE, 160
- Pascual-Salcedo D: See Jochems GJ, 57
Perkins S, Zimmermann U, and Foung SKH: Parameters to enhance human hybridoma formation with hypoosmolar electrofusion, 155
Platsoucas CD: See Kunicka JE, 160
Posner M: See Kresina TF, 42
Posner MR, Elboim HS, Tumber MB, Wiest PM, and Tibbets LM: An IgG human monoclonal antibody reactive with a surface membrane antigen expressed on malignant breast cancer cells, 74
Prather K: See McKnight ME, 190
- Robinson RR, Chartier J, Jr., Chang CP, Horwitz AH, and Better M: Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities, 84
Rondeau P: See Brodeur BR, 194

- Sato S: See Hashizume S, 51, 142; Hirose H, 200; Kato M, 94; Mochizuki K, 116
 Seki H: See Kunicka JE, 160
 Shinmoto H, Dosako S, Tachibana H, Yamada K, Shirahata S, and Murakami H: Generation of hybrid hybridomas secreting human IgM class hybrid antiricin and antidipteria toxin antibodies, 39
 Simonsson AC, Larrick JW, Borrebaeck CAK: In vitro immunization of human B lymphocytes. MAPPING of lymphokine specific mRNA and the effect of recombinant factors, 148
 Shirahata S: See Shinmoto H, 39
 Steplewski Z: See Blottière HM, 16
 Strelkauskas AJ, Aldenderfer PH, and Warner GA: Human monoclonal antibody JDB, reacts with cytoplasmic and membrane bound antigens present on a variety of human breast tumor cell lines, 207
 Sundqvist V-A: See Gustafsson B, 26
 Swana GT: See De Silva MG, 11
 Tachibana H: See Shinmoto H, 39
 Tackaberry ES: See Larose Y, 67
 Tai H: See Hashizume S, 142; Hirose H, 200
 Tamaki S: See Hirose H, 200
 Tan KS: See De Silva MG, 11
 Thomson J: See Gauny SS, 33
 Tibbetts LM: See Posner MR, 74
 Tokiyoshi S: See Maeda H, 124
 Tsuchimoto K: See Hashizume S, 51
 Tumber MB: See Posner MR, 74
 van Boxtel-Oosterhof F: See Jochems GJ, 57
 van Lier RAW: See Jochems GJ, 57
 Waever-Rasmussen J: See Erb K, 215
 Warner GA: See Strelkauskas AJ, 207
 Wiest PM: See Posner MR, 74
 Winkelhake JL: see Gauny SS, 33
 Wisnewski A; See Kresina TF, 42
 Yamada K: See Shinmoto H, 39
 Yasumoto K: See Hashizume S, 51, 142; Hirose H, 200; Kato M, 94
 Young JD: See Gauny SS, 33
 Zeijlemaker WP: See Jochems GJ, 57
 Zimmerman U: See Perkins S, 155

Subject Index

- ADCC, 84
 Antibody engineering, 124
 Anti-carcinoma, 84
 Ascites, 33
 Autocrine factors, 57
 Autoimmunity, 11
 Bactericidal activity, 194
 Biopsy, 200
Bordetella pertussis, 194
 Breast cancer, 74
 Breast tumors, 207
 Cancer marker, 94
 Cancer therapy, 84
Candida krusei, 142
 Carboxypeptidase A, 51
 CDC, 84
 Cell cycle, 160
 Cell surface accessible viral epitopes, 67
 Chimeric antibody, 84, 124
 Clearance rate, 33
 Colon cancer, 135
 COU-1, 135
 Cytochrome *c*, 142
 Cytomegalovirus, 26, 27
 Diabetes mellitus, 11
 Diagnosis, 200
 Effector function, 84
 Electrofusion, 155
 Epstein-Barr virus, 74
 Epstein-Barr virus B-cell lines, 57
 F(ab')₂, 116
 Fusion partner, 26, 102
 Gamma interferon, 16
 Gastro-intestinal tract carcinoma, 16
 Gene mapping, 148
 Heterogeneity, 116
 Heterohybridoma, 67, 102, 194
 Histone H2B, 94
 Human antibody tumor cell lines, 206
 Human anti-murine immunoglobulin, 16
 Human bifunctional antibody, 39
 Human DNA, 102
 Human-human hybridoma, 51
 Human hybridoma, 155
 Human immunodeficiency virus, 124
 Human monoclonal antibodies, 11, 33, 42, 51, 67, 94, 116, 135, 142, 155, 194, 200, 215
 Human T-T cell hybrids, 160
 Human tumor nucleolar antigens, 4
 Hybrid hybridomas, 39
 Hypoosmolar fusion medium, 155
 IgG, 74
 IgM, 33
 IgM antibody, 116
 IL-6, 57
 Immunohistochemistry, 135
 Immunoregulation, 42
 Inhibition of tumor cell growth, 160
 In vitro immunization, 102, 148
 Lipooligosaccharide, 194
 Localization, 215
 LT, 57
 Lung adenocarcinoma, 94
 Lung cancer, 51, 116, 142, 200
 Lymphokine mRNA, 148
 Melanoma, 215
 Monoclonal antibodies, 74, 102, 172, 190, 204
 Monomeric unit, 116
 Mouse-human hybridomas, 39
 NIH-3 mouse, 33
 Novel cell lines, 11
 Peripheral blood lymphocytes, 102
 Pharmacokinetics, 33
 Porcine pancreas, 51
 Recombinant DNA, 172
Schistosoma japonicum, 42
 Schistosomiasis japonica, 42
 Serodiagnosis, 51, 142
 SHFP-1, 190
 SPAM-8, 26
 Sputum, 200
 Suppressor factors, 160
 Surface membrane antigens, 74
 Therapeutic antibodies, 172
 Tissue fixation, 135
 TNF, 57